Tosedostat (CHR-2797) is an inhibitor of aminopeptidases that blocks a critical step in the protein degradation and re-synthesizes intracellular pathway. This orally bioavailable agent has shown promising activity in vitro and in early clinical trials for patients with relapsed/refractory AML (acute myeloid leukaemia) [1]. CHR-2797 demonstrated marked in vitro cytotoxicity in AML samples and strong synergy with Cytarabine (Ara-C), but significantly less cytotoxicity to normal marrow progenitors[2]. Additionally, when given in combination with morphine, tosedostat exerts a synergistic analgesic effect resulting in a reduction of effective dosages required to achieve the same analgesic effect[3]. Tosedostat with capecitabine displayed tolerable toxicity, and prolonged disease control in a subset of patients[4].
搜索
